Literature DB >> 7821891

Immunohistochemical detection of bcl-2 protein in liver lesions: bcl-2 protein is expressed in hepatocellular carcinomas but not in liver cell dysplasia.

M Zhao1, N X Zhang, M Economou, I Blaha, J A Laissue, A Zimmermann.   

Abstract

A proto-oncogene, bcl-2, encodes a protein that inhibits programmed cell death (apoptosis) and may play a role in cell and tissue differentiation. As bcl-2 appears to be involved in the turn-over of stem or precursor cells, it is thought to be operational in carcinogenesis pathways. However, apart from certain lymphomas, only limited data are available on the frequency of its expression in solid tumors. Immunohistochemical analysis with an antibody specific for bcl-2 protein was used to detect the protein in hepatocellular carcinomas and in one of the putative precursor lesions, liver cell dysplasia. We detected bcl-2 protein in 5 of 37 hepatocellular carcinomas. Immunoreactivity was not related to type, grade, or extent of PCNA staining of the tumours. No bcl-2 protein staining was observed in three types of liver cell dysplasia. Thus, bcl-2 is abnormally expressed in some hepatocellular carcinomas but not in potential tumour precursor cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7821891     DOI: 10.1111/j.1365-2559.1994.tb01323.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  8 in total

1.  Effects of endotoxin on expression of ras, p53 and bcl-2 oncoprotein in hepatocarcinogenesis induced by thioacetamide in rats.

Authors:  J M Yang; D W Han; Q C Liang; J L Zhao; S Y Hao; X H Ma; Y C Zhao
Journal:  World J Gastroenterol       Date:  1997-12-15       Impact factor: 5.742

Review 2.  Histopathological evaluation of apoptosis in cancer.

Authors:  Y Soini; P Pääkkö; V P Lehto
Journal:  Am J Pathol       Date:  1998-10       Impact factor: 4.307

3.  The Ca2+ threshold for the mitochondrial permeability transition and the content of proteins related to Bcl-2 in rat liver and Zajdela hepatoma mitochondria.

Authors:  Y V Evtodienko; V V Teplova; T S Azarashvily; A Kudin; O Prusakova; I Virtanen; N E Saris
Journal:  Mol Cell Biochem       Date:  1999-04       Impact factor: 3.396

4.  Expresssion of bcl-2 oncoprotein in cases of acute and chronic viral hepatitis type B and type C: a clinicopathologic study.

Authors:  Athanassios C Tsamandas; Konstantinos Thomopoulos; Charalambos Gogos; Konstantinos Tepetes; Theodore Kourelis; Panagiota Ravazoula; Theodore Petsas; Dionissis S Bonikos; Chrisoula Karatza; Dionissios D Karavias
Journal:  Dig Dis Sci       Date:  2002-07       Impact factor: 3.199

5.  Increased bcl-2 expression in lymphocytes and its association with hepatocellular damage in patients with autoimmune hepatitis.

Authors:  M Yachida; K Kurokohchi; K Arima; M Nishioka
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

6.  Disruption of Growth Hormone Receptor Signaling Abrogates Hepatocellular Carcinoma Development.

Authors:  Abedul Haque; Vishal Sahu; Jamie Lynne Lombardo; Lianchun Xiao; Bhawana George; Robert A Wolff; Jeffrey S Morris; Asif Rashid; John J Kopchick; Ahmed O Kaseb; Hesham M Amin
Journal:  J Hepatocell Carcinoma       Date:  2022-08-15

7.  Repression of PKR mediates palmitate-induced apoptosis in HepG2 cells through regulation of Bcl-2.

Authors:  Xuerui Yang; Christina Chan
Journal:  Cell Res       Date:  2009-04       Impact factor: 25.617

8.  Immunohistochemically detectable bcl-2 expression in colorectal carcinoma: correlation with tumour stage and patient survival.

Authors:  D Ofner; K Riehemann; H Maier; B Riedmann; H Nehoda; M Tötsch; W Böcker; B Jasani; K W Schmid
Journal:  Br J Cancer       Date:  1995-10       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.